A recent analysis from the Peterson Center on Healthcare and the Kaiser Family Foundation provides an incomplete picture of U.S. spending on health care while downplaying the “immense role” that drug costs play, writes Aaron Wesolowski, AHA’s vice president of policy research, analytics and strategy, for the AHA Stat Blog. Read more.

Related News Articles

Headline
The AHA Feb. 28 filed a friend-of-the-court brief in the U.S. Court of Appeals for the 4th Circuit, urging the court to affirm a decision by the U.S. District…
Headline
Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa, Jan. 23 introduced the Drug-price Transparency for Consumers Act, legislation supported by the AHA that…
Headline
The Department of Health and Human Services Jan. 17 announced 15 Medicare Part D drugs selected for the latest round of price negotiations. Negotiations will…
Headline
Prices for the top 25 brand-name Medicare Part D drugs have increased by an average of 98% since entering the market, according to a report released Jan. 9 by…
Headline
The net prices of five drugs included in a new study from the Institute for Clinical and Economic Review increased without clinical justification in 2023.…
Headline
The AHA Dec. 9 said it supports a potential Medicare $2 Drug List Model, where people enrolled in a Part D plan would have access to certain prescription drugs…